Dana Chase, MD

Panelists discuss how addressing molecular, clinical, and access-related gaps remains essential for advancing endometrial cancer research and care.

Panelists discuss how emerging therapies and biomarker-driven research are shaping the next wave of innovation in endometrial cancer treatment.

Panelists discuss how evolving immunotherapy combinations and NCCN guidelines shape frontline treatment selection for advanced or recurrent endometrial cancer.

Panelists discuss how careful management of adverse events and quality-of-life factors optimizes the safe use of dostarlimab plus chemotherapy in endometrial cancer.

Panelists discuss how survival data from the RUBY study highlight the benefits of dostarlimab plus chemotherapy in pMMR/MSS and older patient populations with advanced endometrial cancer.

At the 2025 ESMO Congress, leading oncologists reflected on data expected to redefine practice across breast, genitourinary, and gynecologic malignancies.

Panelists discuss how patient and disease characteristics guide the selection of frontline immunotherapy regimens in recurrent or metastatic endometrial cancer.

Panelists discuss how molecular testing enables precise categorization of endometrial cancer into biologically distinct subtypes that guide prognosis, therapy selection, and future research direction.

Leading experts across oncology specialties preview the key studies and data they are most anticipating ahead of the 2025 ESMO Congress.

Dana M. Chase, MD, expands on the importance of endometrial cancer awareness month, which is observed annually in September.

Dana M. Chase, MD, discusses the management of recurrent endometrial cancer, emphasizing the importance of biomarker profiles and previous therapies.

Dana M. Chase, MD, discusses how patient preferences can inform treatment planning in gynecologic oncology.

Dana M. Chase, MD, discusses the importance of quality of life and patient-reported outcome measures in gynecologic oncology.

Dana M. Chase, MD, discusses the FDA approval of dostarlimab plus chemotherapy for patients with primary advanced or recurrent endometrial cancer.

Dana Chase, MD, discusses niraparib as frontline maintenance therapy in ovarian cancer.

Dana Chase, MD, gynecologic oncologist, Arizona Oncology, discusses the standard of care for the treatment of patients with uterine leiomyosarcoma.

Dana Chase, MD, gynecologic oncologist, Arizona Oncology, discusses the presentation of uterine sarcomas.